709 related articles for article (PubMed ID: 29753958)
1. Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment.
Ganipineni LP; Danhier F; Préat V
J Control Release; 2018 Jul; 281():42-57. PubMed ID: 29753958
[TBL] [Abstract][Full Text] [Related]
2. Harnessing nanomedicine for therapeutic intervention in glioblastoma.
Gutkin A; Cohen ZR; Peer D
Expert Opin Drug Deliv; 2016 Nov; 13(11):1573-1582. PubMed ID: 27292970
[TBL] [Abstract][Full Text] [Related]
3. Glioblastoma chemotherapeutic agents used in the clinical setting and in clinical trials: Nanomedicine approaches to improve their efficacy.
Aparicio-Blanco J; Sanz-Arriazu L; Lorenzoni R; Blanco-Prieto MJ
Int J Pharm; 2020 May; 581():119283. PubMed ID: 32240807
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticles: Novel vehicles in treatment of Glioblastoma.
Pourgholi F; Hajivalili M; Farhad JN; Kafil HS; Yousefi M
Biomed Pharmacother; 2016 Feb; 77():98-107. PubMed ID: 26796272
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment.
Wang D; Wang C; Wang L; Chen Y
Drug Deliv; 2019 Dec; 26(1):551-565. PubMed ID: 31928355
[TBL] [Abstract][Full Text] [Related]
6. Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials.
Bruinsmann FA; Richter Vaz G; de Cristo Soares Alves A; Aguirre T; Raffin Pohlmann A; Stanisçuaski Guterres S; Sonvico F
Molecules; 2019 Nov; 24(23):. PubMed ID: 31779126
[TBL] [Abstract][Full Text] [Related]
7. Nanocarrier-based drug combination therapy for glioblastoma.
Zhao M; van Straten D; Broekman MLD; Préat V; Schiffelers RM
Theranostics; 2020; 10(3):1355-1372. PubMed ID: 31938069
[TBL] [Abstract][Full Text] [Related]
8. Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma.
Oberoi RK; Parrish KE; Sio TT; Mittapalli RK; Elmquist WF; Sarkaria JN
Neuro Oncol; 2016 Jan; 18(1):27-36. PubMed ID: 26359209
[TBL] [Abstract][Full Text] [Related]
9. Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art.
Karim R; Palazzo C; Evrard B; Piel G
J Control Release; 2016 Apr; 227():23-37. PubMed ID: 26892752
[TBL] [Abstract][Full Text] [Related]
10. Anticancer drug-loaded hydrogels as drug delivery systems for the local treatment of glioblastoma.
Bastiancich C; Danhier P; Préat V; Danhier F
J Control Release; 2016 Dec; 243():29-42. PubMed ID: 27693428
[TBL] [Abstract][Full Text] [Related]
11. Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine.
Kim SS; Harford JB; Pirollo KF; Chang EH
Biochem Biophys Res Commun; 2015 Dec; 468(3):485-9. PubMed ID: 26116770
[TBL] [Abstract][Full Text] [Related]
12. Tumor-targeted nanotherapeutics: overcoming treatment barriers for glioblastoma.
Wadajkar AS; Dancy JG; Hersh DS; Anastasiadis P; Tran NL; Woodworth GF; Winkles JA; Kim AJ
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2017 Jul; 9(4):. PubMed ID: 27813323
[TBL] [Abstract][Full Text] [Related]
13. Current Challenges and Opportunities in Treating Glioblastoma.
Shergalis A; Bankhead A; Luesakul U; Muangsin N; Neamati N
Pharmacol Rev; 2018 Jul; 70(3):412-445. PubMed ID: 29669750
[TBL] [Abstract][Full Text] [Related]
14. Stimuli-Responsive Multifunctional Nanomedicine for Enhanced Glioblastoma Chemotherapy Augments Multistage Blood-to-Brain Trafficking and Tumor Targeting.
Martins C; Araújo M; Malfanti A; Pacheco C; Smith SJ; Ucakar B; Rahman R; Aylott JW; Préat V; Sarmento B
Small; 2023 Jun; 19(22):e2300029. PubMed ID: 36852650
[TBL] [Abstract][Full Text] [Related]
15. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
Khaitan D; Reddy PL; Ningaraj N
Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
[TBL] [Abstract][Full Text] [Related]
16. Delivery across the blood-brain barrier: nanomedicine for glioblastoma multiforme.
Jena L; McErlean E; McCarthy H
Drug Deliv Transl Res; 2020 Apr; 10(2):304-318. PubMed ID: 31728942
[TBL] [Abstract][Full Text] [Related]
17.
Gallego L; Ceña V
Expert Opin Drug Deliv; 2020 Nov; 17(11):1541-1554. PubMed ID: 32791861
[TBL] [Abstract][Full Text] [Related]
18. Temozolomide nanoparticles for targeted glioblastoma therapy.
Fang C; Wang K; Stephen ZR; Mu Q; Kievit FM; Chiu DT; Press OW; Zhang M
ACS Appl Mater Interfaces; 2015 Apr; 7(12):6674-82. PubMed ID: 25751368
[TBL] [Abstract][Full Text] [Related]
19. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy Delivery Strategies to the Central Nervous System: neither Optional nor Superfluous.
Drapeau A; Fortin D
Curr Cancer Drug Targets; 2015; 15(9):752-68. PubMed ID: 26077730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
